{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:02:18Z","timestamp":1792173738644,"version":"4.4.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Alcohol use disorder (AUD) is the most prevalent substance use disorder (SUD) globally. In 2019, AUD affected 14.5 million Americans and contributed to 95,000 deaths, with an annual cost exceeding 250 billion dollars. Current treatment options for AUD have moderate therapeutic effects and high relapse rates. Recent investigations have demonstrated the potential efficacy of intravenous ketamine infusions to increase alcohol abstinence and may be a safe adjunct to the existing alcohol withdrawal syndrome (AWS) management strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We followed Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines to conduct a scoping review of two databases (PubMed and Google Scholar) for peer-reviewed manuscripts describing the use of ketamine in AUD and AWS. Studies that evaluated the use of ketamine in AUD and AWS in humans were included. We excluded studies that examined laboratory animals, described alternative uses of ketamine, or discussed other treatments of AUD and AWS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 204 research studies in our database search. Of these, 10 articles demonstrated the use of ketamine in AUD or AWS in humans. Seven studies investigated the use of ketamine in AUD and three studies described its use in AWS. Ketamine used in AUD was beneficial in reducing cravings, alcohol consumption and longer abstinence rates when compared to treatment as usual. In AWS, ketamine was used as an adjunct to standard benzodiazepine therapy during severe refractory AWS and at signs of delirium tremens. Adjunctive use of ketamine demonstrated earlier resolution of delirium tremens and AWS, reduced ICU stay, and lowered likelihood of intubation. Oversedation, headache, hypertension, and euphoria were the documented adverse effects after ketamine administration for AUD and AWS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of sub-dissociative doses of ketamine for the treatment of AUD and AWS is promising but more definitive evidence of its efficacy and safety is required before recommending it for broader clinical use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1141836","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:37:05Z","timestamp":1682573825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review"],"prefix":"10.3389","volume":"14","author":[{"given":"Charlotte E.","family":"Goldfine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah J.","family":"Tom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana D.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yudkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"5","author":"Degenhardt","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref2","year":"2018"},{"key":"ref3","year":"2019"},{"key":"ref4","year":""},{"key":"ref5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.AMEPRE.2011.06.045","article-title":"Economic costs of excessive alcohol consumption in the U.S., 2006","volume":"41","author":"Bouchery","year":"2011","journal-title":"Am J Prev Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1097\/CCM.0B013E3182A16919","article-title":"Alcohol, nicotine, and iatrogenic withdrawals in the ICU","volume":"41","author":"Awissi","year":"2013","journal-title":"Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccc.2012.07.004","article-title":"Alcohol withdrawal syndrome","volume":"28","author":"Carlson","year":"2012","journal-title":"Crit Care Clin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00115-005-1917-6","article-title":"Identifikation von Risikogenen f\u00fcr Alkoholabh\u00e4ngigkeit. Das NMDA-Rezeptor-System [The NMDA receptor system: genetic risk factor for alcoholism]","volume":"76","author":"Schumann","year":"2005","journal-title":"Nervenarzt"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/sj.npp.1300928","article-title":"The role of opioid receptor subtypes in the development of behavioral sensitization to ethanol","volume":"31","author":"Pastor","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0885066605275353","article-title":"Management of delirium tremens","volume":"20","author":"DeBellis","year":"2005","journal-title":"J Intensive Care Med"},{"key":"ref11","first-page":"1443","article-title":"Alcohol withdrawal syndrome","volume":"69","author":"Bayard","year":"2004","journal-title":"Am Fam Physician"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ANE.12671","article-title":"Alcohol withdrawal syndrome: mechanisms, manifestations, and management","volume":"135","author":"Jesse","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"ref13","first-page":"14","article-title":"Evaluation of adjunctive ketamine to benzodiazepines for Management of Alcohol Withdrawal Syndrome","author":"Wong","year":"2014"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e768","DOI":"10.1097\/CCM.0000000000003204","article-title":"Adjunct ketamine use in the Management of Severe Ethanol Withdrawal","volume":"46","author":"Pizon","year":"2018","journal-title":"Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/S13181-018-0662-8","article-title":"Adjunctive use of ketamine for benzodiazepine-resistant severe alcohol withdrawal: a retrospective evaluation","volume":"14","author":"Shah","year":"2018","journal-title":"J Med Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.15288\/jsads.2014.75.79","article-title":"Pharmacotherapy of alcohol use disorders: seventy-five years of Progress","volume":"75","author":"Zindel","year":"2014","journal-title":"J Stud Alcohol Drugs Suppl"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/J.1530-0277.2011.01523.X","article-title":"The efficacy of disulfiram for the treatment of alcohol use disorder","volume":"35","author":"J\u00f8rgensen","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/J.1360-0443.2012.04054.X","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1097\/01.ALC.0000042011.99580.98","article-title":"Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors","volume":"26","author":"Harris","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jsat.2009.01.004","article-title":"Effectiveness of making alcoholics anonymous easier (MAAEZ), a group format 12-step facilitation approach","volume":"37","author":"Ann Kaskutas","year":"2009","journal-title":"J Subst Abus Treat"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/070674371205700604","article-title":"The effectiveness of psychosocial modalities in the treatment of alcohol problems in adults: a review of the evidence","volume":"57","author":"Martin","year":"2012","journal-title":"Can J Psychiatr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1111\/ACER.14192","article-title":"Prevalence and correlates of past-year recovery from DSM-5 alcohol use disorder: results from National Epidemiologic Survey on alcohol and related conditions-III","volume":"43","author":"Fan","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"m3934","DOI":"10.1136\/BMJ.M3934","article-title":"Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis","volume":"371","author":"Cheng","year":"2020","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/JAMA.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1370\/AFM.884","article-title":"An intervention for treating alcohol dependence: relating elements of medical management to patient outcomes with implications for primary care","volume":"6","author":"Ernst","year":"2008","journal-title":"Ann Fam Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/APS.2016.5","article-title":"Ketamine use in current clinical practice","volume":"37","author":"Gao","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"ref27","year":"2023"},{"key":"ref28","year":"2023"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/APPI.AJP.2020.20081251","article-title":"Synthesizing the evidence for ketamine and Esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1038\/TP.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/APPI.AJP.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"ref32","volume-title":"Psychedelic drugs reconsidered","author":"Grinspoon","year":"1979"},{"key":"ref33","first-page":"377","article-title":"Use of ketamine in the treatment of delirium tremens and medical delirium","volume":"29","author":"Condi","year":"1972","journal-title":"Anesth Analg Reanim"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrn2515","article-title":"The glutamate homeostasis hypothesis of addiction","volume":"10","author":"Kalivas","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/J.1471-4159.2011.07361.X","article-title":"Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J Neurochem"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/APPI.AJP.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am J Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nrn2234","article-title":"Synaptic plasticity and addiction","volume":"8","author":"Kauer","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.NEULET.2015.01.051","article-title":"Molecular mechanisms of synaptic remodeling in alcoholism","volume":"601","author":"Kyzar","year":"2015","journal-title":"Neurosci Lett"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1196\/ANNALS.1300.010","article-title":"NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy","volume":"1003","author":"Krystal","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"710338","DOI":"10.3389\/FPSYT.2021.710338","article-title":"An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: improving therapeutic outcomes with treatment resistant depression","volume":"12","author":"Muscat","year":"2021","journal-title":"Front Psychol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/SCIENCE.1190287\/SUPPL_FILE\/LI.SOM.PDF","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/J.NEUROPHARM.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J Psychoactive Drugs"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1207\/S15473333THP3404_7","article-title":"Ketamine enhanced psychotherapy: Preliminary clinical observations on its effectiveness in treating alcoholism","volume":"34","author":"Kolp","year":"2009","journal-title":"Humanist Psychol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1038\/s41467-019-13162-w","article-title":"Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories","volume":"10","author":"Das","year":"2019","journal-title":"Nat Commun"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/APPI.AJP.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref47","first-page":"152","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","author":"Grabski","year":"2022"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"695335","DOI":"10.3389\/FPSYT.2021.695335","article-title":"\u201cThis is something that changed my life\u201d: a qualitative study of patients\u2019 experiences in a clinical trial of ketamine treatment for alcohol use disorders","volume":"12","author":"Mollaahmetoglu","year":"2021","journal-title":"Front Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/J.NEUBIOREV.2021.05.006","article-title":"Therapeutic potential of ketamine for alcohol use disorder","volume":"126","author":"Worrell","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"109606","DOI":"10.1016\/J.DRUGALCDEP.2022.109606","article-title":"Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: a systematic review and comprehensive analysis of mechanism of actions","volume":"239","author":"Garel","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","article-title":"Ketamine assisted psychotherapy: a systematic narrative review of the literature","volume":"15","author":"Drozdz","year":"2022","journal-title":"J Pain Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/ARCHPSYC.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1141836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:37:09Z","timestamp":1682573829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1141836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":54,"alternative-id":["10.3389\/fpsyt.2023.1141836"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1141836","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1141836"}}